Escherichia coli gene fimA was the most frequent gene that occurred in the intestine of all investigated groups. All subjects with fimA gene had significantly higher values of tumor necrosis factor alpha (TNF-α) and CRP than those with other E. coli genes. There was also a tendency to increased serum interleukin (IL)-6 levels in patients carrying the fimA gene; however, no relation was observed to serum IL-8 and IL-10. Patients with Crohn's disease had significantly higher IL-6 than those with ulcerative colitis (UC) and controls. The highest levels of TNF-α were detected in the UC group. There were no significant differences in serum IL-8 and IL-10 between all three groups. The presence of E. coli gene fimA in the large bowel of patients with IBD is related to the immunological activity of the disease which may be important from the aspect of therapeutical strategy.

Department of Internal Medicine Faculty of Medicine P J Šafárik University Trieda SNP 1 040 11 Košice Slovakia

Zobrazit více v PubMed

Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976;70:439–444. PubMed

Boudeau J, Barnich N, Darfeuille-Michaud A. Type 1 pili-mediated adherence of E. coli strain LF82 isolated from Crohn’s disease is involved in bacterial invasion of intestinal epithelial cells. Mol Microbiol. 2001;39:1272–1284. doi: 10.1111/j.1365-2958.2001.02315.x. PubMed DOI

Chamberli WM, Naser SA. Integrating theories of the etiology of Crohn’s disease: questioning the hypotheses. Med Sci Monit. 2006;12:27–33. PubMed

Denis MA, Reenaers C, Fontaine F, et al. Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohn’s disease with normal C-reactive protein serum level. Inflamm Bowel Dis. 2007;13:1100–1105. doi: 10.1002/ibd.20178. PubMed DOI

Dignass AU, Baumgart DC, Sturm A. Review article: the etiopathogenesis of inflammatory bowel disease—immunology and repair mechanisms. Aliment Pharmacol Ther. 2004;20(Suppl. V):9–17. doi: 10.1111/j.1365-2036.2004.02047.x. PubMed DOI

Dogan B, Simpson KW. Microflora in Crohn’s disease: the emergence of adherent and invasive Escherichia coli. Expert Rev Clin Immunol. 2008;4:133–137. doi: 10.1586/1744666X.4.2.133. PubMed DOI

Douda T, Bureš J, Rejchrt S. Mean platelet volume in Crohn’s disease patients. Cas Lek Cesk. 2006;145:870–873. PubMed

Fantini MC, Monteleone G, MacDonald TT. New players in the cytokine orchestra of inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:1–5. doi: 10.1002/ibd.20212. PubMed DOI

Florin TH, Paterson EW, Fowler EV. Clinically active Crohn’s disease in the presence of a low C reactive protein. Scand J Gastroenterol. 2006;41:306–311. doi: 10.1080/00365520500217118. PubMed DOI

Guarner F, Malagelada JR. Role of bacteria in experimental colitis. Best Pract Res Clin Gastroenterol. 2003;17:793–804. doi: 10.1016/S1521-6918(03)00068-4. PubMed DOI

Irving PM, Pasi KJ, Rampton DS. Thrombosis and inflammatory bowel disease. Clin Gastroenterol Hepatol. 2005;3:617–628. doi: 10.1016/S1542-3565(05)00154-0. PubMed DOI

Kuhnert P, Hacker J, Muhldorfer I, et al. Detection system for Escherichia coli-specific virulence genes: absence of virulence determinants in B and C strains. Appl Environ Microbiol. 1997;63:703–709. PubMed PMC

Liptáková A, Sehnálková H, Sabol M, et al. Detection of shiga-like toxin producing Escherichia coli by multiplex PCR. Biologia Bratislava. 2001;56:65–68.

Macfarlane S, Steed H, Macfarlane GT. Intestinal bacteria and inflammatory bowel disease. Crit Rev Clin Lab Sci. 2009;46:25–54. doi: 10.1080/10408360802485792. PubMed DOI

Martin HM, Campbell BJ, Hart CA, et al. Enhanced E. coli adherence and invasion in Crohn’s disease and colon cancer. Gastroenterology. 2004;127:1649–1650. doi: 10.1053/j.gastro.2004.09.072. PubMed DOI

Mitsuyama K, Tomiyasu N, Takaki K. IL-10 in the pathophysiology of inflammatory bowel disease: increased serum concentrations during the recovery phase. Med Inflamm. 2006;1:1–7. doi: 10.1155/MI/2006/26875. PubMed DOI PMC

Mudter J, Neurath MF. IL-6 signaling in inflammatory bowel disease: pathophysiology role and clinical relevance. Inflamm Bowel Dis. 2007;13:1016–1023. doi: 10.1002/ibd.20148. PubMed DOI

Nielsen OH, Rudiger N, Gaustadnes M, et al. Intestinal interleukin-8 concentration and gene expression in inflammatory bowel disease. Scand J Gastroenterol. 1997;32:1028–1034. doi: 10.3109/00365529709011220. PubMed DOI

Reinecker HC, Steffen M, Witthoeft T, et al. Enhanced secretion of tumour necrosis factor-α, IL-6, and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn’s disease. Clin Exp Immunol. 1993;94:174–181. doi: 10.1111/j.1365-2249.1993.tb05997.x. PubMed DOI PMC

Sanchez-Muñoz F, Dominguez-Lopez A, Yamamoto Furusho JK. Role of cytokines in inflammatory bowel disease. World J Gastroenterol. 2008;14:4280–4288. doi: 10.3748/wjg.14.4280. PubMed DOI PMC

Sansonetti PJ, Arondel J, Huerre M. IL-8 controls bacterial transepithelial translocation at cost of epithelial destruction in experimental shigellosis. Infect Immun. 1999;67:1471–1480. PubMed PMC

Sasaki M, Sitaraman SV, Babbin BA, et al. Invasive Escherichia coli are a feature of Crohn’s disease. Lab Invest. 2007;87:1042–1054. doi: 10.1038/labinvest.3700661. PubMed DOI

Scaldaferri F, Fiocchi C. Inflammatory bowel disease: progress and current concepts of etiopathogenesis. J Dig Dis. 2007;8:1–9. doi: 10.1111/j.1751-2980.2007.00310.x. PubMed DOI

Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis: a randomised study. New Engl J Med. 1987;317:1625–1629. doi: 10.1056/NEJM198712243172603. PubMed DOI

Vermèire S, van Assche G, Rutgeerts P. Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut. 2006;55:426–431. doi: 10.1136/gut.2005.069476. PubMed DOI PMC

Yamamoto S, Terai A, Yuri K, et al. Detection of virulence factors in Escherichia coli by multiplex polymerase chain reaction. FEMS Immunol Med Microbiol. 1995;12:85–90. doi: 10.1111/j.1574-695X.1995.tb00179.x. PubMed DOI

Dynamics of predominant microbiota in the human gastrointestinal tract and change in luminal enzymes and immunoglobulin profile during high-altitude adaptation